Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
Exploring Analyst Estimates for Pfizer (PFE) Q4 Earnings, Beyond Revenue and EPS
10:16am, Thursday, 30'th Jan 2025
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quar
Dividends And Dynamite: 10 High-Yield Blue-Chip Bargains You Don't Want To Miss
07:00am, Thursday, 30'th Jan 2025
A “Dividend and Dynamite” approach that pairs ultra‐yielding blue chips with top‐tier growth stocks, delivering not only robust current income but also strong long‐term appreciation and 3X m
10 Undervalued Dividend Growth Stocks: January 2025
09:00am, Wednesday, 29'th Jan 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, an
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
08:00am, Wednesday, 29'th Jan 2025
Biotech stocks will need to brace for political "games" Wednesday as the Senate meets to potentially confirm RFK Jr. to lead HHS. The post The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senat
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
06:50pm, Tuesday, 28'th Jan 2025
In the latest trading session, Pfizer (PFE) closed at $26.75, marking a -0.41% move from the previous day.
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
03:11pm, Tuesday, 28'th Jan 2025
Ahead of next Tuesday's earnings release, Pfizer seems undervalued based on current price of $26.55 & valuation of $150bn. But is it madness to expect upside? Quite possibly it is. My DCF analysis sug
PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor
11:26am, Tuesday, 28'th Jan 2025
A Bloomberg article suggests activist investor Starboard cut Pfizer some slack by not nominating any director on the company's board this year.
Here's How to Play Pfizer Stock Before Q4 Earnings Release
10:20am, Tuesday, 28'th Jan 2025
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
06:45am, Tuesday, 28'th Jan 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Ca
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
06:15am, Tuesday, 28'th Jan 2025
When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to the S&P 500 over holding periods of 20+ years. This outperformance stems from
Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients
02:23pm, Monday, 27'th Jan 2025
On Saturday, Pfizer Inc. PFE revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leu
5 Large Cap Growth Stocks With Dividend Yields Up to 8% Are Too Cheap to Ignore
07:19am, Monday, 27'th Jan 2025
Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.
Have $500? 2 High-Yield Dividend Stocks to Buy Right Now
09:30am, Sunday, 26'th Jan 2025
Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the years. While not all dividend stocks are the same, finding great companies th
Inflation Just Won't Go Away: Stick With These 5 High-Yield Dividend Giants
05:17pm, Saturday, 25'th Jan 2025
The recent inflation data is undoubtedly far better than the 9.1% increase reported in the summer of 2022.
Pfizer's BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
03:00pm, Saturday, 25'th Jan 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERB
